AngioDynamics (NASDAQ:ANGO) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of AngioDynamics (NASDAQ:ANGO – Free Report) from a hold rating to a buy rating in a research note issued to investors on Saturday.

Other research analysts also recently issued research reports about the stock. Canaccord Genuity Group increased their price objective on shares of AngioDynamics from $15.00 to $17.00 and gave the company a “buy” rating in a report on Wednesday, July 16th. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of AngioDynamics in a research report on Wednesday, July 16th. Finally, Lake Street Capital began coverage on shares of AngioDynamics in a research report on Wednesday, July 16th. They issued a “buy” rating and a $24.00 price target on the stock.

View Our Latest Stock Report on ANGO

AngioDynamics Stock Up 0.1%

Shares of AngioDynamics stock opened at $8.78 on Friday. AngioDynamics has a 52 week low of $5.83 and a 52 week high of $13.50. The stock’s 50-day simple moving average is $9.40 and its 200-day simple moving average is $9.63. The company has a market capitalization of $356.73 million, a price-to-earnings ratio of -10.58 and a beta of 0.67.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last posted its quarterly earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.09. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%. The company had revenue of $80.16 million for the quarter, compared to analysts’ expectations of $74.26 million. During the same period in the previous year, the firm earned ($0.06) EPS. The firm’s revenue was up 13.0% compared to the same quarter last year. On average, equities analysts expect that AngioDynamics will post -0.37 earnings per share for the current year.

Hedge Funds Weigh In On AngioDynamics

Large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC increased its position in AngioDynamics by 359.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock valued at $54,000 after acquiring an additional 4,268 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of AngioDynamics during the 2nd quarter worth about $90,000. ProShare Advisors LLC bought a new position in AngioDynamics during the 4th quarter valued at about $100,000. Graham Capital Management L.P. bought a new position in AngioDynamics during the 4th quarter valued at about $106,000. Finally, OneDigital Investment Advisors LLC raised its position in AngioDynamics by 14.0% in the 4th quarter. OneDigital Investment Advisors LLC now owns 12,137 shares of the medical instruments supplier’s stock worth $111,000 after purchasing an additional 1,490 shares during the period. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

(Get Free Report)

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.

Featured Stories